StockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017

LOS ANGELES, July 7, 2016

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Update with Aeolus Pharmaceuticals, Inc. – Biodefense and Biotechnology Company Discusses Clinical Development and Milestones for 2016-2017

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals is developing a platform of novel compounds, known as metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy.  The Company is also developing AEOL 11114 as a treatment for Parkinson's disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies.  For more information, please visit Aeolus's corporate website at www.aolsrx.com.